J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

Johnson & Johnson (NYSE:JNJ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ...

“The Phase 3 Vivacity-MG3 data demonstrates our steadfast pursuit of researching and developing potential innovative and ...

SAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in ...

The filing is based on the results of the Vivacity-MG3 study, which showed an improvement with nipocalimab compared to placebo on activities of daily living scores that J&J says have not been seen ...

The results from the Vivacity-MG3 study, presented at the European Academy of Neurology (EAN), show an improvement with nipocalimab compared to placebo on activities of daily living scores that ...

Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were ...

Get the next trade alert free. Johnson & Johnson JNJ on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension (OLE), evaluating ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...